of the CY 2025 OPPS/ASC final rule with comment period, for qualifying non-opioid products, we finalized applying an 18 percent payment limitation on the volume weighted payment average of the top 5 services associated with the use of the qualifying non-opioid product
The total annual cost for cohort 1 was $482,449 for the ODB vitamin B12 prescription claims and $2.1 million for the intramuscular injection claims (Table 2)
The companies that shut down generally shared common risk factors: aggressive marketing practices, thin quality documentation, overly broad product catalogs mixing peptides with SARMs or controlled substances, and pricing that undercut the cost of legitimate synthesis
This is one of the most effective synergies in the entire protocol
Specifically, analyzed were the affected brain areas (04), cerebral (NTP-7, Level 3), cerebellar cortex (NTP-7, Level 6), and hippocampus, thalamus, and hypothalamus (NTP-7, Level 3) as follows (score 0 indicates no histopathologic change): score 1: small, patchy, complete, or incomplete infarcts (10% of the area affected)
Log book to track when and where you do injections